Innovator companies have employed a variety of multipronged
strategies to counter biosimilar competition. These include
development of ‘biobetter’, gaining regulatory approval for additional
indications and new formulations. Karen Lipworth, Jill Dawson,
Raymond A. Huml, and Nigel R. Rulewski, of QuintilesIMS, discuss
why these products have potential to improve drug access for
patients while cutting healthcare costs.